Comparative Pharmacology
Head-to-head clinical analysis: SODIUM CHROMATE CR 51 versus XENON XE 133 V S S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM CHROMATE CR 51 versus XENON XE 133 V S S.
SODIUM CHROMATE CR 51 vs XENON XE 133-V.S.S.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiolabeled sodium chromate (51Cr) binds to red blood cells, tagging them for survival studies. 51Cr emits gamma radiation, allowing detection and quantification of RBC mass and survival via scintillation counting or imaging.
Xenon Xe-133 is a radioactive gas that emits beta and gamma radiation. It distributes to the lungs and is used for ventilation-perfusion imaging. Its mechanism is based on regional distribution in the lungs, reflecting ventilation. It does not have pharmacological activity.
Intravenous injection, 5-30 microcuries (0.185-1.11 MBq) as a single dose.
5-10 mCi (185-370 MBq) inhaled as a single dose for pulmonary ventilation imaging.
None Documented
None Documented
The biological half-life is approximately 27–30 days. Clinically, gradual clearance from blood and tissues occurs over weeks to months.
Terminal elimination half-life of approximately 3.5 minutes, corresponding to rapid washout from lungs following cessation of inhalation.
Primarily renal. Approximately 90% of absorbed dose is excreted in urine within 48 hours. Fecal excretion accounts for less than 5%.
Eliminated almost entirely via exhalation through the lungs (>95%); negligible renal or biliary/fecal excretion.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical